太龙药业
(600222)
| 流通市值：40.17亿 | | | 总市值：40.17亿 |
| 流通股本：5.74亿 | | | 总股本：5.74亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 762,431,550.01 | 323,274,192.26 | 1,941,420,111.64 | 1,340,673,177.46 |
| 营业收入 | 762,431,550.01 | 323,274,192.26 | 1,941,420,111.64 | 1,340,673,177.46 |
| 二、营业总成本 | 749,190,272.42 | 322,639,972.49 | 1,921,754,800.48 | 1,346,043,360.06 |
| 营业成本 | 574,172,789.53 | 236,600,285.06 | 1,444,561,462.62 | 985,570,955.51 |
| 税金及附加 | 5,246,855.65 | 1,572,180.71 | 11,124,987.01 | 7,410,862.93 |
| 销售费用 | 57,991,234.75 | 30,720,537.57 | 170,931,092.61 | 128,370,951.44 |
| 管理费用 | 59,052,299.36 | 25,969,539.22 | 136,651,190.44 | 103,411,846.52 |
| 研发费用 | 25,905,142.62 | 13,172,018.42 | 100,890,903.52 | 77,116,859.71 |
| 财务费用 | 26,821,950.51 | 14,605,411.51 | 57,595,164.28 | 44,161,883.95 |
| 其中:利息费用 | 24,752,329.05 | 14,352,082.15 | 56,327,640.25 | 40,711,845.95 |
| 其中:利息收入 | 369,998 | 124,555.1 | 3,638,212.43 | 761,678.54 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,451,657.5 | 142,972.13 | 7,937,549.17 | 6,120,927.47 |
| 加:投资收益 | -596,645.68 | -40,568.62 | 2,736,772.52 | 1,051,330.44 |
| 资产处置收益 | 0 | - | 129,923.84 | 111,634.85 |
| 资产减值损失(新) | 9,807,663.33 | -387,281.99 | -7,323,009.67 | 4,532,018.37 |
| 信用减值损失(新) | -4,038,964.37 | 873,975.88 | 3,549,825.06 | 11,307,523.99 |
| 其他收益 | 4,632,227.94 | 1,412,310.43 | 9,022,958.85 | 6,919,004.89 |
| 四、营业利润 | 24,497,216.31 | 2,635,627.6 | 35,719,330.93 | 24,672,257.41 |
| 加:营业外收入 | 40,204.12 | 37,177.97 | 182,436.99 | 9,336.98 |
| 减:营业外支出 | 178,694.73 | 27,060.01 | 827,514.15 | 260,602.31 |
| 五、利润总额 | 24,358,725.7 | 2,645,745.56 | 35,074,253.77 | 24,420,992.08 |
| 减:所得税费用 | 1,757,047.75 | 14,602.57 | -18,421,214.92 | -5,526,534.22 |
| 六、净利润 | 22,601,677.95 | 2,631,142.99 | 53,495,468.69 | 29,947,526.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 22,601,677.95 | 2,631,142.99 | 53,495,468.69 | 29,947,526.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,346,600.25 | 1,530,570.06 | 50,525,319.37 | 28,895,857.99 |
| 少数股东损益 | 3,255,077.7 | 1,100,572.93 | 2,970,149.32 | 1,051,668.31 |
| 扣除非经常损益后的净利润 | 15,194,442.43 | 457,856.98 | 37,344,167.99 | 19,486,835.65 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0 | 0.09 | 0.05 |
| (二)稀释每股收益 | 0.04 | 0 | 0.09 | 0.05 |
| 八、其他综合收益 | -6,722,238.08 | -6,596,422.14 | -17,475,736.43 | -5,779,588.77 |
| 归属于母公司股东的其他综合收益 | -6,722,238.08 | -6,596,422.14 | -17,475,736.43 | -5,779,588.77 |
| 九、综合收益总额 | 15,879,439.87 | -3,965,279.15 | 36,019,732.26 | 24,167,937.53 |
| 归属于母公司股东的综合收益总额 | 12,624,362.17 | -5,065,852.08 | 33,049,582.94 | 23,116,269.22 |
| 归属于少数股东的综合收益总额 | 3,255,077.7 | 1,100,572.93 | 2,970,149.32 | 1,051,668.31 |
| 公告日期 | 2025-08-27 | 2025-04-30 | 2025-04-09 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |